Source: International Congress 2019 – Crosstalk in chronic pulmonary diseases



Rating:

Share or cite this content

Citations should be made in the following way:
F. Dasi Fernandez (Valencia, Spain), S. Pastor (Valencia, Spain), M. Magallón (Valencia, Spain), S. Castillo (Valencia, Spain), D. Pellicer (Valencia, Spain), L. Bañuls (Valencia, Spain), M. Navarro-García (Valencia, Spain), A. Escribano (Valencia, Spain). Plasma circulating miRNAs as diagnostic and prognostic biomarkers in alpha-1 antitrypsin deficiency.. 5415

Member's Comments

No comment yet.

Related content which might interest you: Serum TNFα, CD14 and CRP levels in COPD patients with different alpha-1 antitrypsin phenotypes Source: Annual Congress 2008 - Advances in functional genomics of neoplastic and non-neoplastic lung diseases Year: 2008 Circulating total leptin as a diagnostic and prognostic biomarker in sepsis Source: International Congress 2019 – ECMO, ECCO2R and other rescue therapies in acute respiratory failure Year: 2019 Evaluation of CCL18 serum levels and genetic variant as prognostic biomarkers in SSc-ILD Source: Virtual Congress 2021 – Prognostic markers of disease progression in non-idiopathic pulmonary fibrosis interstitial lung diseases Year: 2021 Plasma protein profiling in alpha-1-antitrypsin deficiency Source: Annual Congress 2011 - Molecular: pathology of infectious and inflammatory lung disease Year: 2011 Free plasmatic circulating DNA as prognostic and diagnostic lung cancer biomarker Source: Annual Congress 2008 - Novel trends in functional genomics and molecular pathology of neoplastic and non-neoplastic lung diseases Year: 2008 Serum kinetics of total leptin and soluble leptin receptor as prognostic tools in sepsis. Source: International Congress 2019 – Biomarkers, laboratory findings and pre-clinical data in acute respiratory failure Year: 2019 The evaluation of serum biomarkers in patients with sarcoidosis: Can visfatin be a new biomarker for sarcoidosis? Source: International Congress 2017 – Rare diseases Year: 2017 Study of angiotensin-converting enzyme, serum amyloid A, soluble interleukin-2 receptor, lysozyme and KL-6 in serum as diagnostic markers in pulmonary sarcoidosis Source: Annual Congress 2007 - Sarcoidosis: various aspects Year: 2007 Serum amyloid A as a potential biomarker of sarcoidosis Source: Annual Congress 2011 - Lung development and neoplasia Year: 2011 The prognostic value of CT-based lung density histograms in patients with severe alpha-1 antitrypsin deficiency Source: Eur Respir J 2004; 24: Suppl. 48, 296s Year: 2004 Elevated circulating concentrations of adiponectin in sarcoidosis – a new marker of disease? Source: Annual Congress 2006 - Clinical features and disease markers of sarcoidosis Year: 2006 The serum levels of endothelin (ET-1); an activation marker and prognostic indicator in sarcoidosis? Source: Eur Respir J 2005; 26: Suppl. 49, 80s Year: 2005 Usefulness of serum procalcitonin in lung cancer patients with elevated serum C-reactive protein level Source: Annual Congress 2011 - Instructive clinical aspects of lung cancer Year: 2011 Elevation of circulating endothelial cell levels in lung cancer – a new prognostic and/or predictive marker? Source: Annual Congress 2008 - Diagnosis and prognosis in thoracic oncology Year: 2008 Serum CC16 is a potential predictor for IPF diagnosis and prognosis Source: Virtual Congress 2020 – Prognosis and biomarkers of idiopathic pulmonary fibrosis Year: 2020 Characterisation of alpha-1 antitrypsin protein expression and secretion in natural killer cells from healthy volunteers and alpha-1 antitrypsin deficiency patients Source: Virtual Congress 2021 – Novel insights into the pathogenesis of chronic lung diseases Year: 2021 Blood leukocyte levels as potential prognostic markers in IPF Source: Virtual Congress 2021 – Biomarkers and e-health in idiopathic interstitial pneumonia Year: 2021 The serum YKL-40 is a useful biomarker for asthma Source: International Congress 2017 – Techniques to treat asthma Year: 2017 Serum biomarkers in SSc-ILD: association with presence, severity and prognosis Source: International Congress 2019 – From biomarkers to treatment of immune-mediated interstitial lung disease: what’s new? Year: 2019